Swedish Venture Capital Faces Fundraising Challenges Amid Investor Uncertainty

Swedish venture capital and life science companies are grappling with fundraising efforts and investor confidence amid financial pressures. Iconovo, a life science firm, has planned two share issues totaling around 49.6 million kronor to ensure continued operations for at least 12 months. The first is a directed share issue of about 25 million kronor targeted at major shareholders Färna Invest and FSG, linked to Systemair founder Gerald Engström and entrepreneur Christer Fåhraeus, the two largest shareholders. The second is a rights issue of approximately 24.6 million kronor, fully backed by board members and existing shareholders, including Engström and Fåhraeus. Notably, the share price is set at 1.15 kronor, reflecting a 20% discount, and total dilution could reach 45%. Approval is sought at a special general meeting scheduled for December 15. Despite Engström becoming a significant shareholder in fall 2023 following a prior directed issue when Iconovo’s stock had dropped 61% since listing, the stock has plunged approximately 87% since then. Fåhraeus pointed out severe challenges facing Sweden's life science sector, with companies without revenue listed on platforms like Spotlight or First North losing on average 97% in value over four years.

In parallel, Litorina’s venture capital arm, Layer Group, is planning a 100 million kronor share issue to avoid breaching loan covenants. However, significant shareholder dissatisfaction has emerged, and several owners have expressed unwillingness to participate, exposing a loss of trust in the major owner. These developments highlight the difficult environment for Swedish venture capital fundraising and the cautious stance of investors amid ongoing financial instability.